These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 36514282)

  • 1. Oral ponesimod in relapsing-remitting multiple sclerosis: a randomised phase II trial.
    Olsson T; Boster A; Fernández Ó; Freedman MS; Pozzilli C; Bach D; Berkani O; Mueller MS; Sidorenko T; Radue EW; Melanson M
    J Neurol Neurosurg Psychiatry; 2014 Nov; 85(11):1198-208. PubMed ID: 24659797
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sphingosine 1-phosphate receptor modulators in multiple sclerosis treatment: A practical review.
    Coyle PK; Freedman MS; Cohen BA; Cree BAC; Markowitz CE
    Ann Clin Transl Neurol; 2024 Apr; 11(4):842-855. PubMed ID: 38366285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bioavailable central nervous system disease-modifying therapies for multiple sclerosis.
    Hartung HP; Cree BAC; Barnett M; Meuth SG; Bar-Or A; Steinman L
    Front Immunol; 2023; 14():1290666. PubMed ID: 38162670
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patients' Preferences for Sphingosine-1-Phosphate Receptor Modulators in Multiple Sclerosis Based on Clinical Management Considerations: A Choice Experiment.
    Keenan A; Whichello C; Le HH; Kern DM; Fernandez GS; Turner V; Das A; Quaife M; Ross AP
    Patient; 2024 May; ():. PubMed ID: 38748388
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reversible oxidation/reduction steps in the metabolic degradation of the glycerol side chain of the S1P
    Treiber A; Seeland S; Segrestaa J; Lescop C; Bolli MH
    Xenobiotica; 2024 Apr; 54(4):182-194. PubMed ID: 38400854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progressive multiple sclerosis: latest therapeutic developments and future directions.
    Faissner S; Gold R
    Ther Adv Neurol Disord; 2019; 12():1756286419878323. PubMed ID: 31598138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting Sphingosine-1-Phosphate Signaling in Breast Cancer.
    Nagahashi M; Miyoshi Y
    Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542328
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Computational analysis of five neurodegenerative diseases reveals shared and specific genetic loci.
    Maselli F; D'Antona S; Utichi M; Arnaudi M; Castiglioni I; Porro D; Papaleo E; Gandellini P; Cava C
    Comput Struct Biotechnol J; 2023; 21():5395-5407. PubMed ID: 38022694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathogenic sphingosine 1-phosphate pathway in psoriasis: a critical review of its pathogenic significance and potential as a therapeutic target.
    Zhao Y; Zhang Y; Li J; Zhang N; Jin Q; Qi Y; Song P
    Lipids Health Dis; 2023 Apr; 22(1):52. PubMed ID: 37072847
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative Efficacy of Relapsing Multiple Sclerosis Therapies: Model-Based Meta-Analyses for Confirmed Disability Accumulation and Annualized Relapse Rate.
    Hennessy B; Zierhut ML; Kracker H; Keenan A; Sidorenko T
    Mult Scler Relat Disord; 2022 Aug; 64():103908. PubMed ID: 35803162
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Benefits of sphingosine-1-phosphate receptor modulators in relapsing MS estimated with a treatment sequence model.
    Corsten CEA; Huygens SA; Versteegh MM; Wokke BHA; Smets I; Smolders J
    Mult Scler Relat Disord; 2023 Dec; 80():105100. PubMed ID: 37944195
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Pharmacokinetics of Ponesimod, a Selective S1P1 Receptor Modulator, in the Treatment of Multiple Sclerosis.
    Kruger TM; Valenzuela B; Thompson CD; Ouwerkerk-Mahadevan S; Ruixo JJP
    Clin Pharmacokinet; 2023 Nov; 62(11):1533-1550. PubMed ID: 37776485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ponesimod: An Oral Second-Generation Selective Sphingosine 1-Phosphate Receptor Modulator for the Treatment of Multiple Sclerosis.
    Alnaif A; Oiler I; D'Souza MS
    Ann Pharmacother; 2023 Aug; 57(8):956-965. PubMed ID: 36514282
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ponesimod for the treatment of relapsing multiple sclerosis.
    Baldin E; Lugaresi A
    Expert Opin Pharmacother; 2020 Nov; 21(16):1955-1964. PubMed ID: 32808832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study: A Randomized Clinical Trial.
    Kappos L; Fox RJ; Burcklen M; Freedman MS; Havrdová EK; Hennessy B; Hohlfeld R; Lublin F; Montalban X; Pozzilli C; Scherz T; D'Ambrosio D; Linscheid P; Vaclavkova A; Pirozek-Lawniczek M; Kracker H; Sprenger T
    JAMA Neurol; 2021 May; 78(5):558-567. PubMed ID: 33779698
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.